HEAR's industry currently sports an average PEG of 2.24. This metric is used similarly to the famous P/E ratio, but the PEG ratio also takes into account the stock's expected earnings growth rate. HEAR is also sporting a PEG ratio of 0.93. HEAR is currently sporting a Zacks Rank of #1 (Strong Buy) and an A for Value. One company value investors might notice is Turtle Beach ( HEAR Quick Quote HEAR - Free Report). When paired with a high Zacks Rank, "A" grades in the Value category are among the strongest value stocks on the market today. For example, value investors will be interested in stocks with great grades in the "Value" category. Zacks has developed the innovative Style Scores system to highlight stocks with specific traits. Value investors use fundamental analysis and traditional valuation metrics to find stocks that they believe are being undervalued by the market at large. Of these, perhaps no stock market trend is more popular than value investing, which is a strategy that has proven to be successful in all sorts of market environments. Nevertheless, we know that our readers all have their own perspectives, so we are always looking at the latest trends in value, growth, and momentum to find strong picks. In addition to factors previously disclosed in Emmaus’ reports filed with the Securities and Exchange Commission and those identified elsewhere in this communication, the following factors, among others, could cause actual results to differ materially from forward-looking statements and historical performance: the risk that no established trading market develops for Emmaus common stock and warrants, which could have a material adverse effect on the marketability and trading prices of the securities and the risks and uncertainties relating to future revenue growth.The proven Zacks Rank system focuses on earnings estimates and estimate revisions to find winning stocks. Forward-looking statements speak only as of the date they are made, and Emmaus assumes no duty to update forward-looking statements. These forward-looking statements are subject to numerous assumptions, risks and uncertainties which change over time. For more information, please visit Forward-looking StatementsĮxcept for the historical information contained herein, the matters discussed in this press release are forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, as amended. is a commercial-stage biopharmaceutical company engaged in the discovery, development, marketing and sale of innovative treatments and therapies, including those in the rare and orphan disease categories.
0 Comments
Leave a Reply. |